Related Experiment Videos
Reinduction chemotherapy for acute nonlymphocytic leukemia
Mayo Clinic Proceedings
|September 1, 1984
Summary
Patients with relapsed acute nonlymphocytic leukemia re-treated with a similar chemotherapy regimen achieved a second remission. A longer initial remission duration predicted a higher chance of success with the three-drug reinduction regimen.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Relapse of acute nonlymphocytic leukemia (ANLL) after initial remission presents a significant clinical challenge.
- Re-treatment strategies for ANLL relapse aim to achieve durable second remissions.
Purpose of the Study:
- To evaluate the efficacy of re-treatment with a similar chemotherapy program in patients with relapsed acute nonlymphocytic leukemia.
- To identify factors predicting the achievement of a second remission.
Main Methods:
- Twenty-four patients with relapsed ANLL were re-treated with a regimen similar to their initial induction therapy.
- A specific three-drug reinduction regimen (cytosine arabinoside, an anthracycline, 6-thioguanine) was administered to a subset of patients.
Main Results:
- Eight out of nine patients who received the three-drug reinduction regimen achieved a second remission.
- A duration of initial remission exceeding 26 weeks was associated with a greater probability of achieving a second remission.
Conclusions:
- Re-treatment of relapsed acute nonlymphocytic leukemia with a similar chemotherapy program can induce second remissions.
- The duration of the initial remission is a significant predictor for successful reinduction therapy in ANLL.